TY - JOUR
T1 - Niraparib treatment for patients with BRCA-mutated ovarian cancer
T2 - review of clinical data and therapeutic context
AU - González-Martín, Antonio
AU - Matulonis, Ursula A
AU - Korach, Jacob
AU - Mirza, Mansoor R
AU - Moore, Kathleen N
AU - Wu, Xiaohua
AU - York, Whitney
AU - Gupta, Divya
AU - Lechpammer, Stanislav
AU - Monk, Bradley J
PY - 2022/7
Y1 - 2022/7
N2 - We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).
AB - We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).
UR - http://www.scopus.com/inward/record.url?scp=85134159373&partnerID=8YFLogxK
U2 - 10.2217/fon-2022-0206
DO - 10.2217/fon-2022-0206
M3 - Review
C2 - 35791804
SN - 1479-6694
VL - 18
SP - 2505
EP - 2536
JO - Future oncology (London, England)
JF - Future oncology (London, England)
IS - 23
ER -